MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition.
about
Targeting CDK4 and CDK6: From Discovery to TherapyCDK4/6 Inhibitors in Cancer Therapy: A Novel Treatement Strategy for Bladder Cancer.Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma.PERK Is a Haploinsufficient Tumor Suppressor: Gene Dose Determines Tumor-Suppressive Versus Tumor Promoting Properties of PERK in Melanoma.Oral nano-delivery of anticancer ginsenoside 25-OCH3-PPD, a natural inhibitor of the MDM2 oncogene: Nanoparticle preparation, characterization, in vitro and in vivo anti-prostate cancer activity, and mechanisms of action.Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA.Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial.Cell cycle proteins as promising targets in cancer therapyLiposarcoma: Multimodality Management and Future Targeted Therapies.PKCι depletion initiates mitotic slippage-induced senescence in glioblastomaStromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor Growth.The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies.Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells.ATRX is a regulator of therapy induced senescence in human cells.Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6CDK4/6 inhibitor: from quiescence to senescence.Clinical and Molecular Spectrum of Liposarcoma.Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas.Drug-resistance in doxorubicin-resistant FL5.12 hematopoietic cells: elevated MDR1, drug efflux and side-population positive and decreased BCL2-family member expression.Mechanistic understanding of the role of ATRX in senescence provides new insight for combinatorial therapies with CDK4 inhibitors.Cell-Cycle Therapeutics Come of Age.Thermal proteome profiling of breast cancer cells reveals proteasomal activation by CDK4/6 inhibitor palbociclib.Alternative lengthening of telomeres phenotype and loss of ATRX expression in sarcomas.CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once ThoughtPalbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in -mutant non-small cell lung cancer
P2860
Q28082912-74E18792-E928-46AA-AE18-F4F943BB3076Q33614544-1B4E85E0-FA60-4323-9246-17037384295EQ33907588-D25E86C0-5C42-44E7-862C-45C83FD5B2F8Q36224716-7172D26F-A14D-47F3-8648-B14BD8C0B104Q36356343-CD701802-D87D-4A2B-BCB6-8CE7A201A249Q36562082-5EE174FB-D037-457D-9E15-C8F42A98EF5EQ37189243-B7B7F1F4-ED21-4727-9959-E13500B7E47BQ37693690-25C59024-9E6B-47C2-A250-E1F36FD0D950Q38824691-CCC9965D-66C4-4963-B161-745DEE20C89CQ38981503-69DED71D-3911-4554-8D25-5A43F55061F0Q39048659-F610D463-8317-4B61-A2E3-C27625339A7FQ39183079-6E2E1D83-AB9E-4F67-9308-FE3F00F72F7FQ41002619-5C679387-2FFA-4500-AFE5-3B369F652266Q41565938-01503850-6772-43CD-998A-B1BCDDE6FEAAQ42775668-934FA5A4-E34F-420C-85D8-481A61A989E7Q43135029-5FA04EC2-1AC3-4466-827C-A4004ECB82E5Q47315579-BB953326-E0A7-4636-A76B-EC223CC45B66Q47444902-89BC4421-C048-44F1-8A27-F8E3264C10E8Q49882954-99BF70B3-4BAC-410D-B746-1210EB26A831Q50195464-74A5C95B-A0EE-4A05-A27B-EA697E976A49Q50959563-B136401C-80A3-4A89-9428-A28915F00B36Q52718493-25DDB6F1-2197-4D0C-9C13-2C337B03D912Q54985797-B89BD52D-58A2-4E4A-BE62-60341AA589A3Q57176702-33BA4438-3F18-4A49-87C9-63F77BB9A5ABQ58801080-E0A1FE6B-6412-43B6-8855-A2F571F6FFB0
P2860
MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
MDM2 turnover and expression o ...... n response to CDK4 inhibition.
@ast
MDM2 turnover and expression o ...... n response to CDK4 inhibition.
@en
type
label
MDM2 turnover and expression o ...... n response to CDK4 inhibition.
@ast
MDM2 turnover and expression o ...... n response to CDK4 inhibition.
@en
prefLabel
MDM2 turnover and expression o ...... n response to CDK4 inhibition.
@ast
MDM2 turnover and expression o ...... n response to CDK4 inhibition.
@en
P2093
P2860
P50
P356
P1433
P1476
MDM2 turnover and expression o ...... in response to CDK4 inhibition
@en
P2093
David D Liu
Fatima O Wilder
Gary K Schwartz
Mark A Dickson
Mary E Klein
Nicholas D Socci
Samuel Singer
William D Tap
P2860
P304
P356
10.18632/ONCOTARGET.3364
P407
P577
2015-04-01T00:00:00Z